Royalty Pharma To Acquire Royalties And Milestones On Frexalimab Owned By ImmuNext For ~$525M In Cash Including Estimated Transaction Costs
Royalty Pharma To Acquire Royalties And Milestones On Frexalimab Owned By ImmuNext For ~$525M In Cash Including Estimated Transaction Costs
Under the terms of ImmuNext's licensing agreement with Sanofi, ImmuNext is entitled to receive an upward tiering net royalty ranging from a high-single digit to low-double digit percentage of worldwide net sales of frexalimab. As a result of today's announced transaction, Royalty Pharma will receive 100% of net royalties on annual worldwide net sales of frexalimab of up to $2.0 billion and share a minority of the royalties above this threshold with ImmuNext shareholders.
根據ImmunExt與賽諾菲簽訂的許可協議條款，Immunext有權獲得向上分級的淨特許權使用費，其佔弗雷沙利單抗全球淨銷售額的百分比從高個位數到低兩位數的百分比不等。根據今天宣佈的交易，Royalty Pharma將獲得不超過20億美元的frexalimab全球年淨銷售額的100％淨特許權使用費，並與ImmunExt股東分享超過該門檻的少數特許權使用費。
In addition, the acquisition will include substantial potential milestone payments from Sanofi. Royalty Pharma estimates frexalimab, if approved, will generate royalties through 2041.
此外，此次收購還將包括來自賽諾菲的大量潛在里程碑付款。Royalty Pharma估計，如果獲得批准，弗雷沙利單抗將在2041年之前產生特許權使用費。
Frexalimab, in development by Sanofi, is a first-in-class, second generation anti-CD40 ligand monoclonal antibody.
Frexalimab由賽諾菲開發，是同類首創的第二代抗CD40配體單克隆抗體。